RhIL-11 treatment normalized Th1/Th2 and T-bet/GATA-3 imbalance in in human immune thrombocytopenic purpura (ITP)
| Autor: | Ying Lin, Yunhua Bao, Xiahui Pan, Muqing He, Xiaoji Lin, Xieming Zhou, Baoling Zhu, Wenjian Guo, Qianqian Li, Limin Jin, Rongxin Yao |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Platelets Male 0301 basic medicine medicine.medical_specialty Adolescent T-Lymphocytes medicine.medical_treatment Immunology GATA3 Transcription Factor Peripheral blood mononuclear cell Hemorrhagic disorder Young Adult 03 medical and health sciences 0302 clinical medicine Immune system Downregulation and upregulation hemic and lymphatic diseases Internal medicine Humans Immunology and Allergy Medicine Platelet Th1-Th2 Balance Aged Aged 80 and over Pharmacology Purpura Thrombocytopenic Idiopathic business.industry hemic and immune systems Immunotherapy Middle Aged Interleukin-11 medicine.disease Thrombocytopenic purpura Interleukin 11 Treatment Outcome 030104 developmental biology Endocrinology 030220 oncology & carcinogenesis Female T-Box Domain Proteins business |
| Zdroj: | International Immunopharmacology. 38:40-44 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2016.05.002 |
| Popis: | Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disorder characterized by reduction in platelet counts. T helper 1 (Th1) cells polarization with an increased shift of Th1/Th2 ratio has been reported in ITP. This shift is associated with transcription factor T-box expressed in T cells (T-bet) upregulation and GATA-binding protein 3 (GATA-3) downregulation, leading to an increased T-bet/GATA-3 ratio. Our previous in vitro study showed that recombinant human interleukin-11 (rhIL-11) could normalize Th1/Th2 imbalance in the peripheral blood mononuclear cells (PBMCs) isolated from adult ITP patients, which co-occurred with T-bet/GATA-3 ratio restoration. In this report, we investigated whether rhIL-11 had therapeutic effect in clinical ITP patients and whether rhIL-11 treatment could normalize Th1/Th2 and T-bet/GATA-3 levels in vivo. We found rhIL-11 treatment had a response rate of 67.7% and significantly decreased Th1 and T-bet levels but increased Th2 and GATA-3 levels in ITP patients who showed good response, normalizing Th1/Th2 and T-bet/GATA-3 ratios similar to that in healthy controls. Thus our study suggested rhIL-11 was effective with tolerable adverse effects in ITP. The treatment strategy warrants further clinical investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect